Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

DTC Clinical Trials - NCI

Trial Name Clinicaltrials.gov NCT Number Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel NCT04449549 * 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People with Adva

By Recovery & Performance Peptides Editorial Team
Trial NameClinicaltrials.gov NCT Number
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelNCT04449549*
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People with Advanced Solid TumorsNCT03366116
Metarrestin (ML-246) in Subjects with Metastatic Solid TumorsNCT04222413
Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable CancerNCT03816345
Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, DURVA+ TrialNCT03907475
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasNCT04750928
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients with Tumors That Have Alterations in DNA Repair GenesNCT05687110
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid TumorsNCT05687136
Studying TAK-243 in Patients with Advanced CancerNCT06223542
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients with Metastatic Solid CancersNCT06606990
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377
A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM)NCT05333458
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly Selected Solid Tumors (ComBET)NCT05327010
Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid TumorsNCT05691517
Randomized Trial of Neratinib, a Pan-ErbB Inhibitor Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors (ComboMATCH Treatment Trial N5)NCT06126276

*Study is open only for the following histologic subtypes: clear cell ovarian cancer, anal cancer, granulosa cell ovarian cancer, and ewing sarcoma
** Prior PARP required

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

02

Question drills

Open a question for its connected answer.

01What Happens Next?+

The panel’s recommendations do not mean that the FDA has approved the six peptides, nor does it make these drugs immediately available through compounding pharmacies. “The misreading I’d most want to head off is people treating this as an FDA seal of approval,” Ash says. “It is important to note that a committee’s recommendation is not the same as FDA approval, and it does not mean these peptides have been proven safe or effective,” Jew says, noting that the panel’s recommendations are also not binding. “The FDA has the authority to overrule the recommendation if it deems that the evidence or public health considerations warrant a different decision.”

SOURCE / www.everydayhealth.com ↗
Continue reading

Related articles